These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36064096)

  • 61. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study.
    Desai RJ; Gagne JJ; Lii J; Liu J; Friedman S; Kim SC
    CMAJ; 2017 Nov; 189(47):E1438-E1447. PubMed ID: 29180383
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
    Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Churchill S; Karlson EW; Murphy SN; Kohane I; Liao KP
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1141-8. PubMed ID: 25864945
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Dai C; Wang YN; Tian WN; Huang YH; Jiang M
    Int Immunopharmacol; 2022 Nov; 112():109269. PubMed ID: 36182873
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.
    Julsgaard M; Hvas CL; Gearry RB; Gibson PR; Fallingborg J; Sparrow MP; Bibby BM; Connell WR; Brown SJ; Kamm MA; Lawrance IC; Vestergaard T; Svenningsen L; Baekdal M; Kammerlander H; Walsh A; Boysen T; Bampton P; Radford-Smith G; Kjeldsen J; Andrews JM; Subramaniam K; Moore GT; Jensen NM; Connor SJ; Wildt S; Wilson B; Ellard K; Christensen LA; Bell SJ
    Inflamm Bowel Dis; 2020 Jan; 26(1):93-102. PubMed ID: 31141607
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
    Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Decreased Risk of Preeclampsia in Women with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.
    Patel NB; Vinsard DG; Kattah AG; Kane SV
    Dig Dis Sci; 2023 Sep; 68(9):3557-3561. PubMed ID: 37402980
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety Analysis of Preoperative Anti-TNF-α Therapy in Pediatric IBD After Intestinal Resection: A Systematic Review and Meta-analysis.
    Bajzát D; Kéri AF; Imrei M; Kói T; Párniczky A; Hegyi P; Kovács K; Váncsa S; Müller KE
    Inflamm Bowel Dis; 2023 Dec; 29(12):1971-1980. PubMed ID: 36789751
    [TBL] [Abstract][Full Text] [Related]  

  • 69. TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide.
    Pache I; Rogler G; Felley C
    Swiss Med Wkly; 2009 May; 139(19-20):278-87. PubMed ID: 19452290
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease].
    Kim JH; Kim JW
    Korean J Gastroenterol; 2017 Oct; 70(4):162-168. PubMed ID: 29060953
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.
    Axelrad J; Bernheim O; Colombel JF; Malerba S; Ananthakrishnan A; Yajnik V; Hoffman G; Agrawal M; Lukin D; Desai A; McEachern E; Bosworth B; Scherl E; Reyes A; Zaidi H; Mudireddy P; DiCaprio D; Sultan K; Korelitz B; Wang E; Williams R; Chen L; Katz S; Itzkowitz S;
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):58-64. PubMed ID: 26247164
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
    Vedamurthy A; Gangasani N; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease.
    Dolovich C; Bernstein CN; Singh H; Nugent Z; Tennakoon A; Shafer LA; Marrie RA; Sareen J; Targownik LE
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1200-1208.e1. PubMed ID: 32668341
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Previous cancer and/or lymphoma in patients with refractory IBD--pro: anti-TNF or immunosuppressive treatment.
    Laharie D
    Dig Dis; 2014; 32 Suppl 1():116-21. PubMed ID: 25531363
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
    Meyer A; Drouin J; Weill A; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2021 Aug; 54(3):302-311. PubMed ID: 34162011
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Monitoring for Extra-Intestinal Cancers in IBD.
    Sifuentes H; Kane S
    Curr Gastroenterol Rep; 2015 Nov; 17(11):42. PubMed ID: 26364836
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease.
    Núñez F P; Quera R; Bay C; Castro F; Mezzano G
    J Crohns Colitis; 2022 Aug; 16(7):1168-1176. PubMed ID: 35044449
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study.
    Holmer AK; Luo J; Russ KB; Park S; Yang JY; Ertem F; Dueker J; Nguyen V; Hong S; Zenger C; Axelrad JE; Sofia A; Petrov JC; Al-Bawardy B; Fudman DI; Llano E; Dailey J; Jangi S; Khakoo N; Damas OM; Barnes EL; Scott FI; Ungaro RC; Singh S;
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1598-1606.e5. PubMed ID: 36642291
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cancer-Associated Chemotherapy Induces Less IBD Exacerbations and a Reduction of IBD Medication Afterwards.
    Koc ÖM; van Kampen RJW; van Bodegraven AA
    Inflamm Bowel Dis; 2018 Jun; 24(7):1606-1611. PubMed ID: 29669052
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.